Oncogenic osteomalacia associated with mesenchymal tumor in the middle cranial fossa: a case report

<p>Abstract</p> <p>Introduction</p> <p>Tumor-induced osteomalacia is a paraneoplastic syndrome of hypophosphatemia. Osteomalacia causes multiple bone fractures and severe pain.</p> <p>Case presentation</p> <p>We report the case of a 57-year-old J...

Full description

Bibliographic Details
Main Authors: Chokyu Isao, Ishibashi Kenichi, Goto Takeo, Ohata Kenji
Format: Article
Language:English
Published: BMC 2012-07-01
Series:Journal of Medical Case Reports
Online Access:http://www.jmedicalcasereports.com/content/6/1/181
id doaj-c2f39d1b58bb4903aa66d05341311500
record_format Article
spelling doaj-c2f39d1b58bb4903aa66d053413115002020-11-25T01:05:31ZengBMCJournal of Medical Case Reports1752-19472012-07-016118110.1186/1752-1947-6-181Oncogenic osteomalacia associated with mesenchymal tumor in the middle cranial fossa: a case reportChokyu IsaoIshibashi KenichiGoto TakeoOhata Kenji<p>Abstract</p> <p>Introduction</p> <p>Tumor-induced osteomalacia is a paraneoplastic syndrome of hypophosphatemia. Osteomalacia causes multiple bone fractures and severe pain.</p> <p>Case presentation</p> <p>We report the case of a 57-year-old Japanese man with tumor-induced osteomalacia associated with a middle cranial fossa bone tumor. The tumor was successfully resected by using a middle fossa epidural approach. His phosphate level recovered to a normal range immediately after the surgery.</p> <p>Conclusions</p> <p>It is rare that tumor-induced osteomalacia originates from the middle skull base. This report suggests that, if patients have a clinical and biochemical picture suggestive of tumor-induced osteomalacia, it is crucial to perform a meticulous examination to detect the tumor or the lesion responsible for the tumor. The serum level of fibroblast growth factor 23 is the most reliable marker for evaluating the treatment outcome of tumor-induced osteomalacia.</p> http://www.jmedicalcasereports.com/content/6/1/181
collection DOAJ
language English
format Article
sources DOAJ
author Chokyu Isao
Ishibashi Kenichi
Goto Takeo
Ohata Kenji
spellingShingle Chokyu Isao
Ishibashi Kenichi
Goto Takeo
Ohata Kenji
Oncogenic osteomalacia associated with mesenchymal tumor in the middle cranial fossa: a case report
Journal of Medical Case Reports
author_facet Chokyu Isao
Ishibashi Kenichi
Goto Takeo
Ohata Kenji
author_sort Chokyu Isao
title Oncogenic osteomalacia associated with mesenchymal tumor in the middle cranial fossa: a case report
title_short Oncogenic osteomalacia associated with mesenchymal tumor in the middle cranial fossa: a case report
title_full Oncogenic osteomalacia associated with mesenchymal tumor in the middle cranial fossa: a case report
title_fullStr Oncogenic osteomalacia associated with mesenchymal tumor in the middle cranial fossa: a case report
title_full_unstemmed Oncogenic osteomalacia associated with mesenchymal tumor in the middle cranial fossa: a case report
title_sort oncogenic osteomalacia associated with mesenchymal tumor in the middle cranial fossa: a case report
publisher BMC
series Journal of Medical Case Reports
issn 1752-1947
publishDate 2012-07-01
description <p>Abstract</p> <p>Introduction</p> <p>Tumor-induced osteomalacia is a paraneoplastic syndrome of hypophosphatemia. Osteomalacia causes multiple bone fractures and severe pain.</p> <p>Case presentation</p> <p>We report the case of a 57-year-old Japanese man with tumor-induced osteomalacia associated with a middle cranial fossa bone tumor. The tumor was successfully resected by using a middle fossa epidural approach. His phosphate level recovered to a normal range immediately after the surgery.</p> <p>Conclusions</p> <p>It is rare that tumor-induced osteomalacia originates from the middle skull base. This report suggests that, if patients have a clinical and biochemical picture suggestive of tumor-induced osteomalacia, it is crucial to perform a meticulous examination to detect the tumor or the lesion responsible for the tumor. The serum level of fibroblast growth factor 23 is the most reliable marker for evaluating the treatment outcome of tumor-induced osteomalacia.</p>
url http://www.jmedicalcasereports.com/content/6/1/181
work_keys_str_mv AT chokyuisao oncogenicosteomalaciaassociatedwithmesenchymaltumorinthemiddlecranialfossaacasereport
AT ishibashikenichi oncogenicosteomalaciaassociatedwithmesenchymaltumorinthemiddlecranialfossaacasereport
AT gototakeo oncogenicosteomalaciaassociatedwithmesenchymaltumorinthemiddlecranialfossaacasereport
AT ohatakenji oncogenicosteomalaciaassociatedwithmesenchymaltumorinthemiddlecranialfossaacasereport
_version_ 1725194138175930368